These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30543839)

  • 41. The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol.
    Albayrak G; Korkmaz FD; Tozcu D; Dogan Turacli I
    J Cell Biochem; 2019 Jun; 120(6):10564-10571. PubMed ID: 30628735
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Good response of cadonilimab (PD-1/CTLA-4 bi-specific antibody) to patients with advanced lung adenocarcinoma after immunotherapy resistance: A case report.
    An E; Lu J; Chen L
    Asian J Surg; 2024 Jul; 47(7):3348-3349. PubMed ID: 38609824
    [No Abstract]   [Full Text] [Related]  

  • 43. Small cell transformation of non-small cell lung cancer under immunotherapy: Case series and literature review.
    Imakita T; Fujita K; Kanai O; Okamura M; Hashimoto M; Nakatani K; Sawai S; Mio T
    Thorac Cancer; 2021 Nov; 12(22):3062-3067. PubMed ID: 34622569
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
    Ricciuti B; Arbour KC; Lin JJ; Vajdi A; Vokes N; Hong L; Zhang J; Tolstorukov MY; Li YY; Spurr LF; Cherniack AD; Recondo G; Lamberti G; Wang X; Venkatraman D; Alessi JV; Vaz VR; Rizvi H; Egger J; Plodkowski AJ; Khosrowjerdi S; Digumarthy S; Park H; Vaz N; Nishino M; Sholl LM; Barbie D; Altan M; Heymach JV; Skoulidis F; Gainor JF; Hellmann MD; Awad MM
    J Thorac Oncol; 2022 Mar; 17(3):399-410. PubMed ID: 34740862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report.
    Xie Z; Gu Y; Lin X; Ouyang M; Qin Y; Zhang J; Liu J; Mai S; Zhou C
    Cancer Biol Ther; 2019; 20(9):1172-1175. PubMed ID: 31161851
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
    Ninomaru T; Hata A; Hara S; Komatsu M
    Thorac Cancer; 2022 Aug; 13(16):2394-2397. PubMed ID: 35793695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma.
    Wang S; Xie T; Hao X; Wang Y; Hu X; Wang L; Li Y; Li J; Xing P
    Thorac Cancer; 2021 Oct; 12(19):2585-2593. PubMed ID: 34490724
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Naproxen inhibits spontaneous lung adenocarcinoma formation in Kras
    Kumar G; Madka V; Singh A; Farooqui M; Stratton N; Lightfoot S; Mohammed A; Rao CV
    Neoplasia; 2021 Jun; 23(6):574-583. PubMed ID: 34091121
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Letter to the Editor Concerning Diminished Efficacy of Programmed Death-(Ligand) 1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
    Kus T; Aktas G
    J Thorac Oncol; 2022 Jun; 17(6):e63-e64. PubMed ID: 35623683
    [No Abstract]   [Full Text] [Related]  

  • 50. REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression.
    Sun S; Hu Z; Huang S; Ye X; Wang J; Chang J; Wu X; Wang Q; Zhang L; Hu X; Yu H
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2273-2283. PubMed ID: 31428934
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cell-type specific tumorigenesis with Ras oncogenes in human lung epithelial cells.
    Kumazaki M; Shimomura I; Kiyono T; Ochiya T; Yamamoto Y
    Biochem Biophys Res Commun; 2020 Apr; 525(2):483-490. PubMed ID: 32111352
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
    Esteban-Burgos L; Wang H; Nieto P; Zheng J; Blanco-Aparicio C; Varela C; Gómez-López G; Fernández-García F; Sanclemente M; Guerra C; Drosten M; Galán J; Caleiras E; Martínez-Torrecuadrada J; Fajas L; Peng SB; Santamaría D; Musteanu M; Barbacid M
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24415-24426. PubMed ID: 32913049
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Causative role of PDLIM2 epigenetic repression in lung cancer and therapeutic resistance.
    Sun F; Li L; Yan P; Zhou J; Shapiro SD; Xiao G; Qu Z
    Nat Commun; 2019 Nov; 10(1):5324. PubMed ID: 31757943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.
    Popat S; Wotherspoon A; Nutting CM; Gonzalez D; Nicholson AG; O'Brien M
    Lung Cancer; 2013 Apr; 80(1):1-4. PubMed ID: 23312887
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Small-Cell Lung Cancer Transformation as a Mechanism of Resistance to Pralsetinib in RET-Rearranged Lung Adenocarcinoma: A Case Report.
    Gazeu A; Aubert M; Pissaloux D; Lantuejoul S; Pérol M; Ikhlef N; Bouhamama A; Franceschi T; Swalduz A
    Clin Lung Cancer; 2023 Jan; 24(1):72-75. PubMed ID: 36437214
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report.
    Boby JM; Mohd Ghazali NN; Mani A; George M
    J Med Case Rep; 2022 Nov; 16(1):420. PubMed ID: 36329437
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Whole-exome sequencing explored mechanism of selpercatinib resistance in RET-rearranged lung adenocarcinoma transformation into small-cell lung cancer: a case report.
    Peng Y; Zheng Z; Zewen W; Yanan L; Mingyan Z; Meili S
    BMC Pulm Med; 2023 Dec; 23(1):492. PubMed ID: 38057798
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Simultaneous Acquisition of T790M Mutation and SCLC Transformation during Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma: A Rare Case Report.
    Yazaki T; Kimoto M; Minagawa A; Maruno T; Yamanaka M; Sonehara K; Hama M; Nakamura T; Kanda S; Hanaoka M; Hachiya T
    Am J Case Rep; 2024 Jun; 25():e943466. PubMed ID: 38822519
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis.
    Widick P; Gill RR; Mantia C; Costa DB; Rangachari D
    Clin Lung Cancer; 2020 Jan; 21(1):e6-e9. PubMed ID: 31640925
    [No Abstract]   [Full Text] [Related]  

  • 60. [Immuno-checkpoint inhibitor resistance and strategy in lung cancer].
    Jiang WR; Fang LP; Chang N; Zhang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Jul; 43(7):603-606. PubMed ID: 32629564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.